Compare Booz Allen Hamilton Holding Corporation (BAH) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booz Allen Hamilton Holding Corporation vs Ginkgo Bioworks Holdings Inc — how do they compare? Booz Allen Hamilton Holding Corporation trades at $64.12 (market cap $7.62B), while Ginkgo Bioworks Holdings Inc trades at $8.98 (market cap $590.53M). The key difference: Booz Allen Hamilton Holding Corporation is far larger — about 12.9× Ginkgo Bioworks Holdings Inc's market cap, and Booz Allen Hamilton Holding Corporation pays a 3.71% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| BAH | DNA | |
|---|---|---|
Market Cap | $7.62B | $590.53M |
Sector | Industrials | Health |
52-Week High | $115.95 | $16.14 |
52-Week Low | $59.71 | $5.48 |
Enterprise Value | $11.02B | $627.78M |
Dividend Yield | 3.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Booz Allen Hamilton (BAH) trades at $64.80, up 3.25% in the last session, with a bearish technical signal but strong fundamentals including a P/E of 9.39 and net income margin of 7.59%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. The company announced a partnership with OpenAI and an acquisition to bolster its defense technology portfolio, signaling strategic growth in AI and national security sectors.
Outlook is mixed: analyst consensus price target of $78.17 suggests 20% upside, supported by robust cash flow and government contracts, but risks include high debt levels and market volatility. The stock's current price near the low end of analyst targets indicates potential value, though technical indicators warn of short-term pressure.
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
